Novel insights into the management of brain metastases

Current Opinion in Neurology

Volumn 23, Issue 6, 2010, Pages 556-562

  Gondi, Vinai ^a   Mehta, Minesh P ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

brain metastases; cognitive function; hippocampal avoidance; stereotactic radiosurgery; whole brain radiotherapy

Indexed keywords

CAPECITABINE; CARBOPLATIN; DEXAMETHASONE; EFAPROXIRAL; GADOLINIUM TEXAPHYRIN; LAPATINIB; MEMANTINE; NITROSOUREA DERIVATIVE; TEGAFUR; TEMOZOLOMIDE;

ADD ON THERAPY; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COGNITION; CORTICOSTEROID THERAPY; EVIDENCE BASED MEDICINE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LEARNING; MEMORY; NEUROSURGERY; OVERALL SURVIVAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; STEREOTACTIC RADIOSURGERY; SYSTEMIC THERAPY; TREATMENT RESPONSE; WHOLE BRAIN RADIOTHERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTINEOPLASTIC PROTOCOLS; BRAIN NEOPLASMS; EVIDENCE-BASED MEDICINE; HOSPICE CARE; HUMANS; PALLIATIVE CARE; PROGNOSIS;

EID: 78649630380     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32833f8cb5     Document Type: Review

References (57)

1. Walker AE, Robins M, Weinfeld FD. Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology 1985; 35:219-226.
2. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37:745-751.
3. Sperduto PW, Berkey B, Gaspar LE, et al. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 2008; 70:510-514.
4. Gaspar LE, Scott C, Murray K, et al. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 2000; 47:1001-1006.
5. Sanghavi SN, Miranpuri SS, Chappell R, et al. Radiosurgery for patients with brain metastases: a multiinstitutional analysis, stratified by the RTOG recursive partitioning analysis method. Int J Radiat Oncol Biol Phys 2001; 51:426-434.
6. Agboola O, Benoit B, Cross P, et al. Prognostic factors derived from recursive partition analysis (RPA) of Radiation Therapy Oncology Group (RTOG) brain metastases trials applied to surgically resected and irradiated brain metastatic cases. Int J Radiat Oncol Biol Phys 1998; 42:155-159.
7. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004; 363:1665-1672.
8. Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multiinstitutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 2010; 77:655-661.
9. Sperduto PW. What is your patient's GPA and why does it matter? Managing brain metastases and the cost of hope. Int J Radiat Oncol Biol Phys 2010; 77:643-644.
10. Cairncross JG, Kim JH, Posner JB. Radiation therapy for brain metastases. Ann Neurol 1980; 7:529-541.
11. Li J, Bentzen SM, Renschler M, et al. Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis. Int J Radiat Oncol Biol Phys 2008; 71:64-70.
12. Khuntia D, Brown P, Li J, et al. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 2006; 24:1295-1304.
13. Gaspar LE, Mehta MP, Patchell RA, et al. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96:17-32.
14. Linskey ME, Andrews DW, Asher AL, et al. The role of stereotactic radio-surgery in the management of patients with newly diagnosed brain metas tases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96:45-68.
15. Vecht CJ, Hovestadt A, Verbiest HB, et al. Dose-effect relationship of dexa-methasoneon Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology 1994; 44:675-680.
16. Gaspar LE, Gutin PH, Rogers L, et al. Preirradiation evaluation and management of brain metastases. American College of Radiology. ACR Appropriateness Criteria. Radiology 2000; 215:1105-1110.
17. Ryken TC, McDermott M, Robinson PD, et al. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96:103-114.
18. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322:494-500.
19. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 1993; 33:583-590.
20. Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996; 78:1470-1476.
21. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998; 280:1485-1489.
22. Kalkanis SN, Kondziolka D, Gaspar LE, et al. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96:33-43.
23. Kondziolka D, Patel A, Lunsford LD, et al. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 1999; 45:427-434.
24. Aoyama H, Shirato H,Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006; 295:2483-2491.
25. Aoyama H, Tago M, Kato N, et al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 2007; 68:1388-1395.
26. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradia tion: a randomised controlled trial. Lancet Oncol 2009; 10:1037-1044.
27. Mueller RP, Soffietti R, Abacioglu MU, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery for surgical resection of 1-3 cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2009; 27 (15S):abstract 2008.
28. Guerrieri M, Wong K, Ryan G, et al. A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from nonsmall cell carcinoma of the lung. Lung Cancer 2004; 46:107-111.
29. Ushio Y, Arita N, Hayakawa T, et al. Chemotherapy of brain metastases from lung carcinoma: a controlled randomized study. Neurosurgery 1991; 28:201-205.
30. Antonadou D, Paraskevaidis M, Sarris G, et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002; 20:3644-3650.
31. Verger E, Gil M, Yaya R, et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 2005; 61:185-191.
32. Suh JH, Stea B, Nabid A, et al. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol 2006; 24:106-114.
33. Suh J, Stea B, Tankel K, et al. Phase III enrich (RT-016) comparative study of efaproxiral administered concurrent with whole brain radiation therapy (WBRT) in women with brain metastases from breast cancer. In: Society for Neuro-Oncology. 12th Annual Meeting; Dallas, Texas, USA; 2007.
34. Mehta MP, Rodrigus P, Terhaard CH, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003; 21:2529-2536.
35. Mehta MP, Shapiro WR, Phan SC, et al. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in nonsmall-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys 2009; 73:1069-1076.
36. Mehta MP, Paleologos NA, Mikkelsen T, et al. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96:71-83.
37. Olson JJ, Paleologos NA, Gaspar LE, et al. The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. J Neurooncol 2010; 96:115-142.
38. Gril B, Palmieri D, Bronder JL, et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 2008; 100:1092-1103.
39. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabinefor HER2-positive advanced breast cancer. N Engl J Med 2006; 355:2733-2743.
40. Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009; 15:1452-1459.
41. DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology 1989; 39:789-796.
42. Li J, Bentzen SM, Renschler M, et al. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neuro-cognitive function. J Clin Oncol 2007; 25:1260-1266.
43. Welzel G, Fleckenstein K, Schaefer J, et al. Memory function before and after whole brain radiotherapy in patients with and without brain metastases. Int J Radiat Oncol Biol Phys 2008; 72:1311-1318.
44. Movsas B, Kae K, Meyers C, et al., editors. Phase III study of prophylactic cranial irradiation vs. observation in patients with stage III nonsmall-cell lung cancer: neurocognitive and quality of life analysis of RTOG 0214. In: American Society of Radiation Oncology Annual Meeting; 2009; Chicago, Illinois, USA.
45. Mizumatsu S, Monje ML, Morhardt DR, et al. Extreme sensitivity of adult neurogenesis to low doses of X-irradiation. Cancer Res 2003; 63:4021-4027.
46. Raber J, Rola R, LeFevour A, et al. Radiation-induced cognitive impairments are associated with changes in indicators of hippocampal neurogenesis. Radiat Res 2004; 162:39-47. (Pubitemid 39044717)
47. Ferrer I, Serrano T, Alcantara S, et al. X-ray-induced cell death in the developing hippocampal complex involves neurons and requires protein synthesis. J Neuropathol Exp Neurol 1993; 52:370-378.
48. Nagai R, Tsunoda S, Hori Y, et al. Selective vulnerability to radiation in the hippocampal dentate granule cells. Surg Neurol 2000; 53:503-507; discussion 6-7.
49. Abayomi OK. Pathogenesis of irradiation-induced cognitive dysfunction. Acta Oncol 1996; 35:659-663.
50. Madsen TM, Kristjansen PE, Bolwig TG, et al. Arrested neuronal proliferation and impaired hippocampal function following fractionated brain irradiation in the adult rat. Neuroscience 2003; 119:635-642.
51. Monje ML, Mizumatsu S, Fike JR, et al. Irradiation induces neural precursor-cell dysfunction. Nat Med 2002; 8:955-962.
52. Peissner W, Kocher M,Treuer H, et al. Ionizing radiation-induced apoptosisof proliferating stem cells in the dentate gyrus of the adult rat hippocampus. Brain Res Mol Brain Res 1999; 71:61-68.
53. Tada E, Parent JM, Lowenstein DH, et al. X-irradiation causes a prolonged reduction in cell proliferation in the dentate gyrus of adult rats. Neuroscience 2000; 99:33-41.
54. Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003; 302:1760-1765.
55. Gondi V, Tolakanahalli R, Mehta MP, et al. Hippocampal-sparing whole-brain radiotherapy: A 'how-to' technique, utilizing helical tomotherapy and LINAC-based intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys 2010 [Epub ahead of print].
56. Gondi V, Tome WA, Marsh J, et al. Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radio therapy: safety profile for RTOG 0933. Radiother Oncol 2010; 95:327-331.
57. Danysz W, Parsons CG, Karcz-Kubicha M, et al. Glycine B antagonists as potential therapeutic agents. Previous hopes and present reality. Amino Acids 1998; 14:235-239.